Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
01/2004
01/01/2004US20040002444 Promote tissue regeneration
01/01/2004US20040002443 Immobilization hemoglobin protein with polyoxyethylene glycol
01/01/2004US20040002068 Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
01/01/2004US20040001892 Tunable, semi-interpenetrating polymer networks (sIPNS) for medicine and biotechnology
01/01/2004US20040001890 Administering by injection; core of biodegradable polymer, drugs and overcoating; sustained released
01/01/2004US20040001889 Short duration depot formulations
01/01/2004US20040001881 Drug in pressure sensitive adhesive; vomiting, nausea therapy; side effect reduction
01/01/2004US20040001872 Using polyoxyethylene glycol solutions; mixing with drug
01/01/2004US20040001871 Lapachone delivery systems, compositions and uses related thereto
01/01/2004US20040001868 Aerosol mixture of lipid crystals with propellant
01/01/2004US20040001867 Vectors for molecule delivery to CD11b expressing cells
01/01/2004US20040001861 Yeast cells cultured in the presence of an alternating electric field having a specific frequency and a specific field strength for a period of time sufficient to increase the capability of the yeast cells to improve the memory of mammals
01/01/2004US20040001860 Dietary supplements for enhancing the immune system
01/01/2004US20040001858 Dietary supplements beneficial for the liver
01/01/2004US20040001838 Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
01/01/2004US20040001835 Prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
01/01/2004US20040001827 Modulate tissue distribution
01/01/2004US20040001806 Culture product containing interleukins and colony stimulanting factor; antitumor agents
01/01/2004US20040001802 Immobilized tumor necrosis factor
01/01/2004US20040001792 Decoloring hair and skin using ascorbic acid
01/01/2004US20040001790 Methods for diagnosis and treatment of tumours
12/2003
12/31/2003WO2004001664A1 Actuation indicator for a dispensing device
12/31/2003WO2004001051A2 Recombinant measles viruses expressing epitopes pf antigens of rna viruses and use of the recombinant viruses for the preparation of vaccine compositions
12/31/2003WO2004001019A2 Novel nanoparticles and use thereof
12/31/2003WO2004001007A2 Buffered formulations for concentrating antibodies and methods of use thereof
12/31/2003WO2004000918A1 Hydrous gel and production process and use of the hydrous gel
12/31/2003WO2004000898A1 Terpolymer of maleic acid, maleic anhydride and alkylvinylether
12/31/2003WO2004000887A1 Compounds that bind to the interferon-gamma, preparation method thereof and medicaments containing same
12/31/2003WO2004000372A2 Disinfecting composition, cleaning tablet produced therefrom, and use thereof
12/31/2003WO2004000369A2 Method of magnetically manipulating a cell with magnetisable particles
12/31/2003WO2004000366A1 Pegylated factor vii glycoforms
12/31/2003WO2004000365A1 Drug transport and delivery system
12/31/2003WO2004000364A1 Preparation containing polydimethylsiloxane for nails, cartilage, bone joint, muscle and tendon disorders
12/31/2003WO2004000362A1 Process for producing block copolymer/drug composite
12/31/2003WO2004000361A1 Metastable pharmaceutical compositions
12/31/2003WO2004000360A1 Use of topical pharmaceutical compositions comprising an active agent and permeation-enhancing base for the manufacture of a medicament to treat various forms of inflammatory dermatosis
12/31/2003WO2004000359A1 Topical pharmaceutical composition comprising skin penetration enhancers for the treatment of warts
12/31/2003WO2004000358A1 Transdermal drug delivery system
12/31/2003WO2004000347A1 Stabilised solid compositions of factor vii polypeptides
12/31/2003WO2004000344A1 Aqueous preparation containing oligopeptides and etherified cyclodextrin
12/31/2003WO2004000325A1 Prostaglandin-containing preparation composition for nasal administration
12/31/2003WO2004000323A1 Medicinal cephem compound composition for injection
12/31/2003WO2004000320A1 Water-based preparation for eye drop
12/31/2003WO2004000296A1 (2s)-2amino-a-{[2-(ethanimidoylamino) ethyl]thio}butanoic acid, a nitric oxide synthase inhibitor, in stabilized pharmaceutical dosage forms
12/31/2003WO2004000291A1 Topical administration of basic antifungal compositions to treat fungal infections of the nails
12/31/2003WO2004000288A1 Fluorosiloxane matrix controlled diffusion drug delivery system
12/31/2003WO2004000287A1 Targeting system comprising uniformly-sized nanoparticles with at least one polymer and at least one positively-charged polysaccharide and preparation method thereof
12/31/2003WO2004000286A1 Microcapsules for the delayed, controlled release of perindopril
12/31/2003WO2004000284A1 Pharmaceutical compositions with improved dissolution
12/31/2003WO2004000283A1 Popping oral administration form
12/31/2003WO2004000282A1 Stable compositions of water sensitive ingredients
12/31/2003WO2004000281A1 Rapidly disintegrating tablet
12/31/2003WO2004000279A1 Solid pharmaceutical composition containing a lipophilic active principle and preparation method thereof
12/31/2003WO2004000278A1 Hybridization signal amplification method (hsam) nanostructures for diagnostic and therapeutic uses
12/31/2003WO2004000275A1 Transdermal aerosol compositions
12/31/2003WO2004000273A1 Oral pharmaceutical forms of liquid drugs having improved bioavailability
12/31/2003WO2004000272A1 Nasal compositions comprising a mucopolysaccharide and propylene glycol
12/31/2003WO2004000271A1 Use of bases for the manufacture of a medicament in the treatment of different forms of inflammatory dermatosis
12/31/2003WO2004000270A1 Sustained-release composition, process for producing the same and preparation thereof
12/31/2003WO2004000269A1 Short duration depot formulations
12/31/2003WO2004000268A1 Topical administration of pharmacologically active bases in the treatment of warts
12/31/2003WO2004000262A1 Process for producing solid bath additive containing shape-retaining matter and humidifying/cooling apparatus
12/31/2003WO2004000245A1 Promoter for uptake of basic amino acid into cell and cosmetic or drug composition
12/31/2003WO2004000235A2 Breath freshening and oral cleansing product with magnolia bark extract
12/31/2003WO2004000234A2 Breath freshening and oral cleansing product with cinnamaldehyde
12/31/2003WO2004000226A2 Liposomes containing biologically active compounds
12/31/2003WO2004000219A2 Stabilized formulations of alpha adrenergic receptor antagonists and uses thereof
12/31/2003WO2004000211A2 Improved compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
12/31/2003WO2004000197A2 Quick dissolve compositions and tablets based thereon
12/31/2003WO2004000116A1 Devices and methodologies useful in body aesthetics
12/31/2003WO2004000034A2 Anthelmintic oral homogeneous veterinary pastes
12/31/2003WO2004000025A1 Use of a composition and a cleaning tablet containing said composition for disinfecting purposes
12/31/2003WO2004000016A2 Antimicrobial compositions, products and methods employing same
12/31/2003WO2003087308A3 Use of interleukin-24 to treat ovarian cancer
12/31/2003WO2003080021A3 Formulation comprising buprenorphine
12/31/2003WO2003075839A3 Methods of inducing terminal differentiation
12/31/2003WO2003072704A3 RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
12/31/2003WO2003066130A3 Transdermal drug delivery systems
12/31/2003WO2003061728A3 Oral administration of interferon-tau
12/31/2003WO2003061621A3 Dermal application system for aminolevulinic acid-derivatives
12/31/2003WO2003059288A3 Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
12/31/2003WO2003059284A3 Composition and method for inhibiting hypersensitivity
12/31/2003WO2003055916A3 Adiponectin fragments and conjugates
12/31/2003WO2003053413A3 Sustained-release compositions
12/31/2003WO2003051334A3 Pharmaceutical composition comprising an oil/water/oil double microemulsion incorporated into a solid support
12/31/2003WO2003047549A3 Post-coated liposome/lipoplex for targeted drug/gene delivery and lipid linked to a delivery, targeting or stabilising moiety
12/31/2003WO2003022996A3 Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
12/31/2003WO2002078747A9 Pregabalin lactose conjugates
12/31/2003WO2002067971A3 Use of endostatin in the treatment of ocular neovascularization
12/31/2003WO2002048110A3 Composition for regulating animal growth, method of manufacture and use thereof
12/31/2003WO2002047615A3 Oral compositions and use thereof
12/31/2003WO2002043750A8 Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations
12/31/2003WO2002042325A3 Cyp1b1 nucleic acids and methods of use
12/31/2003WO2002040055A3 Solutions and films of glycated chitosan
12/31/2003CN2595367Y Plaster back adhesive film
12/31/2003CN1464791A Compositions for protein delivery via the pulmonary route
12/31/2003CN1464790A T cell receptor fusions and conjugates and methods of use thereof
12/31/2003CN1464789A Vaccine against the influenza virus and method for producing said virus vaccine
12/31/2003CN1464774A Improved hard sugar coating method
12/31/2003CN1463750A Emulsifying agent for preparing milky white cod liver oil
1 ... 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 ... 1712